Its preservation in patients with T1DM suggests that DPP-4 inhibitors and GLP-1 agonists may interfere with the progression of autoimmune destruction, a process mediated by a dysregulated immune response [43]. Here, GLP1R is linked to type 1 diabetes mellitus.